Can You Make Your Brain 5 Years Younger?

Guest:Christin Glorioso, MD. Ph.D.Creator of the Younger Biological Aging Contest, Founder & CEO of NeuroAge TherapeuticsLinkedIn: https://www.linkedin.com/in/christin-glorioso-md-phd-39627719/Website: https://www.neuroagetx.com/authors/christin-gloriosoRyan SmithCo-Founder and Director of Research & Development at TruDiagnosticLinkedIn: https://www.linkedin.com/in/ryan-smith-lexington-ky/Website: https://www.trudiagnostic.com/_______________What if measuring biological age could show which interventions actually improve health?Phil Newman sits down with Dr. Christin Glorioso, physician, neuroscientist and founder of NeuroAge and Longevity Global, and Ryan Smith of True Diagnostic to explore the Younger biological aging contest and the future of aging biomarkers.They explain how its six-month challenge combines DNA methylation, proteomics, RNA and glycan clocks with brain imaging and physical-function tests. The resulting data could help compare biomarkers, personalize interventions and strengthen evidence for clinical trials.They also discuss brain health, GLP-1 research, surrogate endpoints and how AI could accelerate biomarker validation.In this episode, you'll learn:- What Younger measures- How multi-omics can refine biological age testing- Which lifestyle factors show promising signals- How brain data can guide personalized recommendations- What biomarkers need before regulators can rely on themThis episode connects emerging aging science with practical routes toward personalized, preventative healthcare.Subscribe for weekly episodes on longevity science, preventative medicine and healthier, longer lives._______________Host: Phil Newman: https://qrco.de/bgXpNY

Guest:Dr. Steven N. Austad, Ph.D.Distinguished Professor of Biology at University of Alabama at BirminghamLinkedIn: https://www.linkedin.com/in/steven-austad-b31b5090/Website: https://www.uab.edu/cas/biology/people/faculty/steven-n-austadAlan Richardson, Ph.D.Professor of Biochemistry & Physiology at University of Oklahoma Health Sciences CenterLinkedIn: https://www.linkedin.com/in/arlan-richardson-357977b3/Website: https://medicine.ouhsc.edu/directory/details/arlan-richardson-phd-1_______________What if some of the best clues to human longevity are already hidden across the animal kingdom?Phil Newman sits down with aging researchers Steven Austad and Arlan Richardson to explore what decades of animal research can teach us about extending human healthspan.Together they explain why mice remain valuable but imperfect models, and how bowhead whales, naked mole rats, bats and 500-year-old clams reveal different biological routes to longevity. They also discuss genetically diverse rats, dietary restriction, fasting and the challenge of translating laboratory discoveries into humans.In this episode, you'll learn:- Why mice alone cannot model human aging- What exceptionally long-lived species reveal- Why genetic diversity matters- How fasting differs from chronic calorie restriction- Why GLP-1s, proteomics and AI could accelerate longevity researchIf you want to understand where longevity research goes next, this episode connects evolutionary biology with emerging human therapeutics.Subscribe for weekly episodes that explore longevity science, preventative med_______________Host: Phil Newman: https://qrco.de/bgXpNY

Guest:Jamie Justice, Ph.D.Executive Director, XPRIZE Healthspan and Vice President of the Health Domain at XPRIZE FoundationLinkedIn: https://www.linkedin.com/in/jamie-justice-ph-d-6b933146/Website: https://www.xprize.org/Steven R. Cummings, MDExecutive Director at S.F. Coordinating Center (SFCC) in the CPMC Research InstituteLinkedIn: https://www.linkedin.com/in/steve-cummings-71668514a/Website: https://www.xprize.org/people/steve-cummings_______________What if the breakthrough longevity needs isn’t another intervention, but a better way to prove what works?Phil Newman sits down with XPRIZE Healthspan director Jamie Justice and judging chair Professor Steven Cummings to explore the $101 million competition.Together they explain why muscle, cognitive and immune function form its evidence framework, and how one-year trials could help model longer-term healthspan gains. From repurposed drugs to gene therapies, finalists must demonstrate measurable effects under common standards.They also discuss FDA pathways, scalability, safety and prevention versus reversal.In this episode, you'll learn:- How finalists are judged- Why function matters beyond biomarkers- How trials model 10–20 years of decline- Why scalability matters- Why safety could determine successIf you want to understand how longevity interventions could become credible medicine, this episode connects rigorous trials with real-world healthspan.Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better._______________Host: Phil Newman: https://qrco.de/bgXpNY

Sponsor: Sooo.meSooo.me™ is a longevity-focused nutraceutical brand offering science-backed supplements designed to support healthy aging, energy, focus, cellular health, and overall wellbeing. Its range combines high-purity ingredients, medicinal mushroom extracts, and targeted formulations with an emphasis on quality, transparency, and sustainable packaging.See what it can do for you — click below to try it today and use code LONGEVITYTECHNO for 10% off.Link: https://sooo.me/?ref=LTUNLOCKED----------Guests:John BeardIrene Diamond Professor and Director International Longevity Center USA, Columbia UniversityLinkedIn: https://www.linkedin.com/in/john-beard-987b801b/Website: https://www.publichealth.columbia.edu/profile/john-beard-mbbs----------What if the way we measure health is holding back the science of aging?Phil Newman sits down with Dr. John Beard, Irene Diamond Professor and Director of the International Longevity Centre USA at Columbia University, to explore intrinsic capacity – measuring health through what people can actually be and do rather than the diseases they have.Together they unpack the five domains of intrinsic capacity and why functional measures could give researchers a more continuous picture of aging. From simple chair-rise and hearing tests to clinical trial endpoints, biomarkers and wearables, Beard explains both the potential and the gaps that remain.They also discuss why “70 is the new 60,” the difference between prevention and health promotion, why some longevity clinics are ahead of the evidence, and how intrinsic capacity could reshape healthcare funding and drug development.In this episode, you'll learn:- Why disease alone is an incomplete measure of aging- How intrinsic capacity measures cognitive, locomotive, psychological, sensory and vitality domains- Why better standardized measures could help shorten aging intervention trials- How early-life health can influence capacity decades later- Why healthcare systems could eventually reward improvements in health rather than throughputIf you want to understand how measuring function could change geroscience, clinical trials and healthcare itself, this episode connects aging biology with practical measures of how well people actually live.Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.----------Host: Phil Newman: https://qrco.de/bgXpNY

Sponsor: Sooo.meSooo.me™ is a longevity-focused nutraceutical brand offering science-backed supplements designed to support healthy aging, energy, focus, cellular health, and overall wellbeing. Its range combines high-purity ingredients, medicinal mushroom extracts, and targeted formulations with an emphasis on quality, transparency, and sustainable packaging.See what it can do for you — click below to try it today and use code LONGEVITYTECHNO for 10% off.Link: https://sooo.me/?ref=LTUNLOCKED----------Guests:Fady Hannah-Shmouni, MD FRCPCFounder & CEO of Hormonaly.aiLinkedIn: https://www.linkedin.com/in/fady-hannah-shmouni/Website: https://shmouni.com/Koehl RobinsonFounder & CEO of Celia HealthLinkedIn: https://www.linkedin.com/in/koehlrobinson/Website: https://www.celia-rx.com/----------What happens when demand for peptide therapies starts moving faster than the science, regulation and clinical infrastructure surrounding them?Phil Newman sits down with Dr. Fady Hannah-Shmouni and Koehl Robinson to explore one of longevity medicine’s fastest-moving areas: peptides. From evidence-backed GLP-1 drugs to compounds such as BPC-157 with far more limited human evidence, they examine where the science is strong, where uncertainty remains and what patients should understand before entering this rapidly expanding market.Together they explore how a cleaner peptide supply chain could work, why testing and clinical oversight matter, and how real-world data could help fill some of the evidence gaps where randomized controlled trials remain limited. They also discuss personalized prescribing, biomarker monitoring, AI and what responsible peptide medicine could look like as the industry matures.In this episode, you'll learn:- Why Fady describes GLP-1s as the standout peptide class, with potential effects extending beyond weight management into appetite and other reward-related behaviors.- Why compounds such as BPC-157 still have major evidence gaps, with much of the published literature remaining preclinical rather than based on high-quality randomized human trials.- How Koehl says Celia RX is building a US-based supply chain with multiple stages of testing, third-party analysis and batch testing to improve transparency around peptide sourcing.- How lab, genomic and epigenetic testing could be combined with consultations and follow-up monitoring to move peptide prescribing toward a more personalized model.- Why AI and real-world multi-omic data could help clinicians make sense of a fragmented evidence base while researchers continue building stronger clinical evidence.The conversation also tackles the uncomfortable reality of the peptide “gray market.” As consumer demand grows, products can vary significantly in sourcing, testing and clinical oversight. Fady and Koehl discuss why transparency around evidence and risk matters, and why better infrastructure may be essential if peptide medicine is going to move further into mainstream healthcare.If you want to understand where peptide medicine stands today – from established therapies to experimental compounds – this episode separates the growing enthusiasm from the evidence still needed to support it.Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.----------Host: Phil Newman: https://qrco.de/bgXpNY

Sponsor: Sooo.meSooo.me™ is a longevity-focused nutraceutical brand offering science-backed supplements designed to support healthy aging, energy, focus, cellular health, and overall wellbeing. Its range combines high-purity ingredients, medicinal mushroom extracts, and targeted formulations with an emphasis on quality, transparency, and sustainable packaging.See what it can do for you — click below to try it today and use code LONGEVITYTECHNO for 10% off.Link: https://sooo.me/?ref=LTUNLOCKED----------Guests:Dr. Christopher ShadeFounder and CEO of Quicksilver ScientificLinkedIn: https://www.linkedin.com/in/dr-christopher-shade-b5a44413/Website: https://www.quicksilverscientific.com/----------What if the biggest problem with your supplements isn’t what you take, but how much actually reaches your cells?Phil Newman sits down with Dr. Christopher Shade, founder and CEO of Quicksilver Scientific, to explore the science of supplement absorption, detoxification and next-generation nutrient delivery.Together they unpack why absorption can vary dramatically between compounds, how liposomal and nanoemulsion systems are designed to improve bioavailability, and why Shade believes detox requires more than short-term cleanses. From his “push-catch” approach to oral peptides, GLP-1 support and NAD+, the conversation examines how delivery could change the way longevity interventions are designed.In this episode, you'll learn:- Why Shade says detoxification needs to address cellular mobilization, liver and bile pathways, and elimination rather than relying on short-term “detox teas” or juice cleanses.- How absorption can vary dramatically between supplements, with Shade citing less than 1% absorption for standard berberine and reporting a 300-fold increase in curcumin absorption using his company’s delivery technology.- Why Quicksilver is exploring oral liposomal versions of peptides including BPC-157, KPV, TB-500, GHK-Cu and epitalin, and why Shade says dose equivalence matters when comparing oral delivery with injections.- Why coming off GLP-1 drugs may require more than simply stopping treatment, with nutrition, exercise and metabolic health forming part of the wider conversation.- How Shade sees the future moving toward personalized supplement stacks guided by biomarkers, genomics and individual response, rather than simply taking more products. The conversation also tackles the increasingly crowded supplement market and the challenge consumers face when trying to distinguish meaningful delivery science from marketing claims. Shade argues that pharmacokinetic data, manufacturing quality and measurable absorption should matter more than simply seeing “liposomal” written on a label.If you want to understand why longevity may depend not only on what you take, but whether your body can actually use it, this episode connects chemistry, supplementation and emerging delivery technologies with a more measured approach to optimizing health.Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.----------Host: Phil Newman: https://qrco.de/bgXpNY

Sponsored by:MuseCell InnovationsMuseCell Innovations is the exclusive global licensor of Dezawa MuseCells®, a naturally occurring, pluripotent-like stem cell platform discovered by Professor Mari Dezawa at Tohoku University. Built on more than 15 years of peer-reviewed research, the company focuses on advancing regenerative medicine across longevity, disease treatment, performance and aesthetics through authenticated cell technology and licensed manufacturing methods.Read more about it here: https://bit.ly/4y0rhpWFree Report:https://longevity.technology/data/report/longevity-biotech-report-2026/Market Model Explorer:https://longevity.technology/data/dashboard-biotech-explorer-tam-and-value/----------In this special Longevity News Roundup, Phil Newman explores the findings behind Longevity.Technology’s latest Longevity Biotech Report, examining investment, market potential, regulation, global competition and regenerative platforms.- More than $30 billion has flowed into longevity biotech in under two years, with investment increasingly concentrated in larger deals and companies with credible clinical programmes.- The report forecasts a potential $617 billion annual global market by 2045, based on assumptions around pricing, population uptake, prevention and the emergence of new healthcare budgets.- The existing pipeline is already projected toward $230 billion in annual revenue through conventional disease indications, with a further $173 billion in potential gerotherapeutic upside if regulatory pathways develop.- Regulatory change could be critical, with ARPA-H’s PROSPR programme, biomarker qualification and future legislative frameworks potentially helping move ageing-related interventions toward multi-disease approval pathways.- China is becoming an increasingly important force, with 59 China-headquartered companies in the tracked cohort raising $16.9 billion and reportedly moving clinical programmes 50–70% faster than US counterparts.- Regenerative platforms such as MuseCell Innovations could offer a more scalable development model, allowing validated platforms to support multiple disease programmes while still requiring indication-specific clinical evidence and regulatory approval.News & References:- $617 billion longevity biotech market takes shape →https://longevity.technology/news/617-billion-longevity-biotech-market-takes-shape/- What is longevity biotech really worth? →https://longevity.technology/news/what-is-longevity-biotech-really-worth/- Longevity biotech’s 100x question →https://longevity.technology/news/longevity-biotechs-100x-question/----------Host: Phil Newman: https://qrco.de/bgXpNY

Sponsor: Sooo.meSooo.me™ is a longevity-focused nutraceutical brand offering science-backed supplements designed to support healthy aging, energy, focus, cellular health, and overall wellbeing. Its range combines high-purity ingredients, medicinal mushroom extracts, and targeted formulations with an emphasis on quality, transparency, and sustainable packaging.See what it can do for you — click below to try it today and use code LONGEVITYTECHNO for 10% off.Link: https://sooo.me/?ref=LTUNLOCKED----------Guests: Elizabeth Poynor, MD, Ph.DChair of Women's Health & Gynecology of Atria Health InstituteLinkedIn: https://www.linkedin.com/in/elizabeth-poynor-md-phd-390491177/Website: https://www.atria.org/doctors/David Dodick, MDChief Medical Officer of Atria Health InstituteLinkedIn: https://www.linkedin.com/in/david-dodick-93a107269/Website: https://www.atria.org/doctors/----------What if protecting women’s brains from dementia needs to begin decades before symptoms appear?Phil Newman sits down with Dr. Elizabeth Poyner and Dr. David Dodick to explore why midlife should be viewed not simply as a reproductive transition, but as a major neurological, hormonal and cardiometabolic one. Together, they examine how fluctuating estrogen during perimenopause can influence brain energetics, sleep, memory and executive function – often before women even recognize they are approaching menopause.Together they explain how fluctuating estrogen can affect brain energetics, why migraine can signal hormonal change, and how insulin resistance, visceral fat and chronic stress can compound brain-health risks. They also unpack the critical window for hormone therapy and why prevention needs a personalized approach.In this episode, you'll learn:Why almost two out of every three Americans living with Alzheimer’s are women, and why longevity alone may not explain the difference.How estrogen fluctuations can affect glucose metabolism, mitochondrial function, sleep and cognitive performance during midlife.Why migraine affects women around three times more often than men and can worsen dramatically during perimenopause.Why optimizing 14 modifiable risk factors could prevent at least 45% of dementia, and why exercise may be one of the most powerful interventions available.How combining hormonal, neurological, metabolic and cardiovascular assessments could enable a more personalized approach to protecting women’s long-term brain health.If you want to understand women’s brain aging, this episode connects hormones, metabolism and neuroscience with practical insights for protecting long-term health.Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.----------Host: Phil Newman: https://qrco.de/bgXpNY

Guests: Paola TelferFounder and CEO of Sens.aiLinkedIn: www.linkedin.com/in/paolatelfer/Website: sens.ai/Eric Verdin, MDPresident and CEO of the Buck Institute for Research on AgingLinkedIn: www.linkedin.com/in/eric-verdin-md/Website: www.buckinstitute.org/----------What if we could track brain aging through function, not just structure?Phil Newman sits down with Paola Telfer, founder and CEO of Sens.ai, and Eric Verdin, president and CEO of the Buck Institute for Research on Aging, to explore BrainYears™, a functional brain age clock designed to measure how the brain performs as it ages.Together they explain how 643 EEG, response and performance variables were analyzed using machine learning to build the BrainYears™ model. They discuss why brain function could complement MRI, retinal, proteomic and epigenetic clocks, and how data collected from people aged 13 to their late 80s helped build the model. The conversation also examines a reported 5.18-year reduction in BrainYears™ following a two-month intervention, while stressing that this early finding still requires prospective, placebo-controlled validation.They also explore neurofeedback, HRV biofeedback and transcranial photobiomodulation, the potential role of BrainYears™ in clinical practice, and Eric’s vision for a scientifically rigorous space between conventional medicine and consumer wellness.In this episode, you’ll learn:Why functional brain aging may be a missing dimension in current aging clocksHow 643 EEG, response and performance variables were narrowed down using machine learning to create the BrainYears™ modelWhy tracking trajectory over time may be more informative than a single biological age scoreWhat the early intervention data showing a reported 5.18-year BrainYears™ reduction actually tells usWhy future validation needs to compare BrainYears™ with MRI-based clocks, proteomics and other measures of brain agingIf you want to understand how brain aging could become measurable, trackable and potentially modifiable earlier in life, this episode explores the science, technology and validation challenges shaping that future.Subscribe for weekly episodes exploring longevity science, preventative medicine and the systems shaping how we live longer and better.----------Host: Phil Newman: https://qrco.de/bgXpNY

In this week’s Longevity News Roundup, Phil Newman examines Oura’s IPO and sleep suit, movement context in dementia, dog gene therapy, Rentosertib biological clocks, and women's health.ŌURA filed for a $16 billion IPO on Nasdaq under ticker Oura, seeking to raise up to $3 billion. Simultaneously, the smart ring company is defending its sleep stage tracking accuracy in a California class action lawsuit alleging its metrics are no better than a coin flip.A 74-study review of 4.2 million people showed leisure movement lowered dementia risk by 24%, while physically demanding jobs increased risk by 20%. This highlights how movement context and recovery matter far more than basic step counts.GenFlow Biosciences reported that its SLAB trial testing SIRT6 gene therapy in 24 aged beagles met its primary endpoint. Treated dogs demonstrated reduced biological age on the Grim methylation clock alongside secondary functional gains.Insilico Medicine published a Phase 2a trial analysis revealing its AI-designed IPF drug Rentosertib reduced predicted biological age. Across six proteomic clocks, patients taking 30 mg twice daily showed three to four years of age reduction.Biograph launched a dedicated women's preventative health program integrated into its concierge membership tiers. The program combines hormone testing, personalized risk assessments, and life-stage care spanning perimenopause, menopause, and cardiovascular health.----------News & References:‘Biograph builds dedicated women’s preventive health arm → https://longevity.technology/news/biograph-builds-dedicated-womens-preventive-health-arm/Rentosertib puts aging clocks to the clinical test → https://longevity.technology/news/rentosertib-puts-aging-clocks-to-the-clinical-test/Genflow Biosciences trial meets primary endpoint in aged dogs → https://longevity.technology/news/genflow-biosciences-trial-meets-primary-endpoint-in-aged-dogs/Study shows the way you move matters more than how often → https://longevity.technology/news/study-shows-the-way-you-move-matters-more-than-how-often/Smart ring maker Oura prepares for US IPO at up to $3b raise → https://longevity.technology/news/smart-ring-maker-oura-prepares-for-u-s-ipo-at-up-to-3b-raise/ŌURA defends its sleep science amid class-action lawsuit → https://longevity.technology/news/oura-defends-its-sleep-science-amid-class-action-lawsuit/----------Host:Phil Newman: https://qrco.de/bgXpNY